SecBot SecBot
Biotech Drug Report Generated Nov 7, 2026

VAX-31

PCVX·Vaxcyte, Inc.
BULLISH
Drug Impact Rating6/10
Trial phase
Phase 3 (adult); Phase 2 (infant)
Time to market
Vaxcyte plans to submit a Biologics License Application (BLA) to the FDA in the first half of 2028, pending completion of OPUS-2, OPUS-3, and a manufacturing consistency study. Assuming a standard 10-12 month FDA review, potential approval would be in the 2029 timeframe at the earliest.
Why 6/10
The next hard, dated catalysts are the OPUS-2 and OPUS-3 Phase 3 topline readouts expected in the first half of 2027 (roughly 4-8 months from now). These are supportive trials for the BLA package, not the primary pivotal study (OPUS-1 already succeeded), so they are less binary. ImpactScore is 6 because VAX-31 is the lead asset driving most of Vaxcyte's value, the catalysts are within ~6-12 months, but the company also has other programs (VAX-24, VAX-A1) and the biggest binary event (OPUS-1) is already past.
Actionable Insight BULLISH

Watch for OPUS-2 and OPUS-3 topline data in H1 2027, which will complete the adult Phase 3 package. Positive results would clear the path for BLA submission in H1 2028. The key risk to monitor is whether the serotype 3 and 12F noninferiority nuance versus Capvaxive becomes a regulatory or commercial issue. The stock has already had its primary binary catalyst (OPUS-1), so subsequent readouts are expected to be supportive but less dramatic movers.

Price Chart

Loading chart...

Executive Summary

VAX-31 is Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate, the broadest in development, designed to prevent invasive pneumococcal disease and pneumonia by covering 31 bacterial serotypes. In October 2026, the pivotal Phase 3 OPUS-1 trial succeeded against both Pfizer's Prevnar 20 and Merck's Capvaxive, driving a large single-day stock gain. Two more Phase 3 readouts (OPUS-2 and OPUS-3) are due in H1 2027, with a BLA submission planned for H1 2028. The company has $3.4 billion in cash and a Strong Buy analyst consensus, but faces entrenched Big Pharma competition and a multi-year path to commercialization.

How It Works

VAX-31 is a 31-valent pneumococcal conjugate vaccine (PCV) designed to train the immune system to recognize and fight 31 different strains (serotypes) of Streptococcus pneumoniae bacteria. It uses Vaxcyte's carrier-sparing technology to pack more serotypes into a single shot than existing vaccines, aiming to prevent invasive pneumococcal disease (IPD), pneumonia, and ear infections caused by these bacteria.

Trial Status

The pivotal Phase 3 adult trial (OPUS-1) enrolled 4,047 adults aged 50+ and met all prespecified co-primary immunogenicity and safety endpoints in October 2026, demonstrating noninferiority versus both Pfizer's Prevnar 20 (PCV20) and Merck's Capvaxive (PCV21). Two additional Phase 3 trials are ongoing: OPUS-2 (concomitant administration with seasonal flu vaccine) and OPUS-3 (adults previously vaccinated). A Phase 2 infant dose-finding study is also underway.

The Two-Sided Case

▲ Bull Case6
OPUS-1 met every prespecified primary endpoint, matching or beating the two leading adult PCV vaccines (Prevnar 20 and Capvaxive) on immunogenicity in a 4,047-patient trial, which drove a ~36% single-day stock gain on October 5, 2026.
VAX-31 covers 31 serotypes, the broadest pneumococcal vaccine candidate in development, versus 20 (Prevnar 20) and 21 (Capvaxive) in currently marketed adult vaccines, addressing a large unmet need as serotype replacement drives residual disease.
The adult pneumococcal vaccine market is estimated at roughly $8 billion annually, with Pfizer's Prevnar franchise generating $6.49 billion in 2025 and Merck's Capvaxive at $759 million, giving VAX-31 a large addressable market if approved.
FDA granted Breakthrough Therapy Designation for VAX-31 for both IPD and pneumonia prevention in adults, which can accelerate development and review timelines.
Vaxcyte has a strong balance sheet with pro forma cash and investments of approximately $3.4 billion as of September 30, 2026, providing runway through at least 2028.
Analyst consensus is Strong Buy with a mean price target of $117.30 (89.4% upside from the $61.92 close on November 6, 2026), with targets ranging from $75 to $163.
▼ Bear Case6
VAX-31 missed the stricter noninferiority bar (LBCI >0.667) on serotypes 3 and 12F versus Capvaxive, though both met the historical LBCI >0.5 threshold; this could be a focus of FDA review or physician adoption concerns.
BLA submission is not expected until the first half of 2028, meaning no FDA approval decision is likely before 2029, leaving the stock without a near-term regulatory catalyst and exposed to execution risk across multiple remaining trials.
The company is pre-revenue and burning cash rapidly (Q3 2026 net loss of $297 million, R&D expense of $270 million), and while the $3.4B cash position is substantial, the burn rate is accelerating.
Insider selling has been consistent: the SVP of Finance sold $1.65 million worth of shares on October 5, 2026 (the day of the positive OPUS-1 data), and both the COO and CAO have executed regular 10b5-1 plan sales throughout Q3/Q4 2026.
Several large institutional holders exited or significantly trimmed positions in Q2 2026, including Baupost Group, Farallon Capital, and Point72 Asset Management, though FMR LLC (Fidelity) added to its position.
VAX-31 faces entrenched competition from Pfizer (Prevnar 20, a $6.5B franchise) and Merck (Capvaxive), both with established manufacturing, sales infrastructure, and CDC/ACIP relationships that could slow market adoption.

Upcoming Catalysts

  • OPUS-2 and OPUS-3 Phase 3 topline readouts expected in first half of 2027
  • Manufacturing consistency study results (timing TBD, ahead of BLA)
  • Phase 2 infant study data readout (timeline not specified)
  • BLA submission planned for first half of 2028

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Vaxcyte, Inc. 8-K PCVX ·Originating report

Sources · 12

Hover a chip for the title
1 investors.vaxcyte.com2 vaxcyte.com3 markets.businessinsider.com4 pharmacytimes.com5 biospace.com6 novapharmanews.com7 investors.vaxcyte.com8 investors.vaxcyte.com9 tikr.com10 marketbeat.com11 panabee.com12 sec.gov